Topchoice Medical
Topchoice Medical Investment Corp. provides medical services.
Topchoice Medical, founded in August, 1995 and headquartered in Hangzhou, is a company providing oral medical and assisted reproductive services. The founder is Lu Jianming. Listed on the SSE on October 30, 1996, the company's major shareholders are Lu Jianming, Bao Zhengliang and Hong Kong Securities Clearing Co. Ltd. Rivals that have direct and indirect competition with Topchoice Medical include Huamei Dental, Bybo Dental, Envista, etc.
Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis
‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’
Jan 30, 2023 02:13 PM
Research
Consumer Staples, Healthcare, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
The investment banking business was strictly supervised, and seven securities companies received fines
SINOVAC Plans to Invest USD 100 Mn in Brazil Starting This Year
EqualOcean has learned that on June 4, Vice President of the Federative Republic of Brazil and Minister of Development, Industry, Trade, and Services, Geraldo Alckmin, met with SINOVAC(科兴) Chairman, President, and CEO Yin Weidong(尹卫东) in Beijing.
Jun 06, 2024 06:18 PM
Cellatopia Secures Nearly CNY Ten Mn in Seed Funding
EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).
Apr 18, 2024 01:25 PM
The first batch of "Mao" concept achievements were released, with a year-on-year growth of more than 50%
Wantai biology: it is proposed to raise no more than 3.5 billion yuan for the phase II expansion project of nine price cervical cancer vaccine
Amazon: the policy is consistent all over the world, and the title is not for Chinese businesses
Zhang Kun's four funds decreased their positions in the second quarter by allocating Wuliangye to Guizhou Maotai
TC Medical's 1H 2020 Revenue Totals CNY 738 Mn, Down 12.87% YoY